Umetsu Michihisa, Hirokawa Masayuki, Fukaya Eri, Teshima Eiichi, Kusagawa Hitoshi, Nishibe Toshiya, Mo Makoto, Ogawa Tomohiro
Division of Vascular Surgery, Department of Surgery, Tohoku University Hospital, Sendai, Japan.
Ochanomizu Vascular and Vein Clinic, Tokyo, Japan.
J Vasc Surg Venous Lymphat Disord. 2025 Mar;13(2):102160. doi: 10.1016/j.jvsv.2024.102160. Epub 2024 Dec 18.
Cyanoacrylate closure (CAC) is a minimally invasive technique for treating axial venous reflux. However, the incidence of serious adverse events (AEs) related to CAC is concerning. With an increasing number of patients undergoing CAC and insufficient safety data in Japan, this study aimed to investigate the safety profile of CAC, focusing on the types and incidence of AEs.
A nationwide survey was conducted by the Japanese Regulatory Committee for Endovascular Treatment of Varicose Veins between November 2023 and December 2023. Data were collected from 1017 institutions, covering 24,209 patients who underwent CAC at 335 institutions between January 2020 and October 2023. Thromboembolism, phlebitis, hypersensitivity reactions, granuloma formation, infection, bleeding, death, and need for glue resection were documented as unfavorable events or outcomes.
Venous thromboembolism developed in 142 patients (0.59%). Pulmonary embolism, proximal deep vein thrombosis, and ablation-related thrombus extension developed in 3 (0.01%), 9 (0.04%), and 95 (0.39%) patients, respectively. Localized phlebitis that required additional treatment was observed in 1656 patients (6.8%). Of the localized hypersensitivity cases, 960 (58%) required oral antihistamines and 268 (16%) required oral and/or intravenous steroids. Furthermore, 65 patients (0.27%) developed systemic hypersensitivity that required systemic steroids. No patients developed a stroke or anaphylaxis. One patient died owing to pulmonary embolism. Glue resection was performed in nine patients with delayed infection (n = 4), hypersensitivity reactions (n = 4), or a foreign body granuloma (n = 1). The incidence of hypersensitivity reactions was similar among institutions. However, the incidence of thrombosis-related events significantly differed between the high-volume and low-volume institutions. The incidence of proximal deep vein thrombosis (0.13% vs 0.01%; P < .001; odds ratio, 12.5; 95% confidence interval, 2.6-60.3) and ablation-related thrombus extension (0.73% vs 0.30%; P < .001; odds ratio, 2.5; 95% confidence interval, 1.66-3.77) was significantly higher in low-volume institutions than in high-volume centers.
A nationwide survey of CAC for varicose veins in Japan demonstrated that it was a safe procedure with a low rate of serious AEs, such as venous thromboembolism. However, hypersensitivity reactions requiring steroid administration and systemic allergic reactions were observed in some patients.
氰基丙烯酸酯封闭术(CAC)是一种治疗轴向静脉反流的微创技术。然而,与CAC相关的严重不良事件(AE)的发生率令人担忧。随着在日本接受CAC治疗的患者数量不断增加且安全数据不足,本研究旨在调查CAC的安全性概况,重点关注AE的类型和发生率。
日本静脉曲张血管内治疗监管委员会在2023年11月至2023年12月期间进行了一项全国性调查。收集了来自1017家机构的数据,涵盖了2020年1月至2023年10月期间在335家机构接受CAC治疗的24209例患者。血栓栓塞、静脉炎、过敏反应、肉芽肿形成、感染、出血、死亡以及胶水切除需求被记录为不良事件或结果。
142例患者(0.59%)发生静脉血栓栓塞。分别有3例(0.01%)、9例(0.04%)和95例(0.39%)患者发生肺栓塞、近端深静脉血栓形成和消融相关血栓扩展。1656例患者(6.8%)观察到需要额外治疗的局限性静脉炎。在局限性过敏病例中,960例(58%)需要口服抗组胺药,268例(16%)需要口服和/或静脉注射类固醇。此外,65例患者(0.27%)发生需要全身类固醇治疗的全身性过敏反应。没有患者发生中风或过敏反应。1例患者因肺栓塞死亡。9例患者因延迟感染(n = 4)、过敏反应(n = 4)或异物肉芽肿(n = 1)进行了胶水切除。各机构间过敏反应的发生率相似。然而,高容量机构和低容量机构之间血栓形成相关事件的发生率存在显著差异。低容量机构近端深静脉血栓形成的发生率(0.13%对0.01%;P <.001;优势比,12.5;95%置信区间,2.6 - 60.3)和消融相关血栓扩展的发生率(0.73%对0.30%;P <.001;优势比,2.5;95%置信区间,1.66 - 3.77)显著高于高容量中心。
日本一项关于静脉曲张CAC的全国性调查表明,这是一种安全的手术,严重AE(如静脉血栓栓塞)发生率较低。然而,在一些患者中观察到需要使用类固醇治疗的过敏反应和全身性过敏反应。